YOLFTbeta
75

Pharmigene, Inc.

7595 · TWO · Healthcare / Diagnostics & Research

8.42TWD+0.12 (+1.45%)

Price History

Full chart

Market Stats

Previous Close8.30
Open8.39
Day Range7.99 – 8.42
52-Week Range5.90 – 11.85
Volume137.01K
Market Cap375.96M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.04
Dividend Yield0.00%
Beta0.01
50-Day Avg7.20
200-Day Avg8.84

About

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variations; whole-genome precision annotation platform; single-cell and spatial transcriptomics data analysis software; precise immune cell identification; automated tissue dissociator; and clinical HLA testing platform. The company was founded in 2005 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Guanzhi Chen
  • HeadquartersNo. 17, Lane 171, Section 2, Jiuzong Road, Taipei, Taiwan, Taiwan
  • Websitehttps://pharmigene.com.tw

Leadership

  • Mr. Guanzhi ChenCOO & Director · b. 1976
  • Mr. Yingzhou XuManager & Representative Director · b. 1960
  • Dr. Yuan-Tsong Chen M.D., Ph.D.Founder

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue65.28M101.35M129.35M133.80M132.71M116.53M199.89M
Growth (%)-+55.26%+27.63%+3.44%-0.82%-12.19%+71.53%
Cost of Revenue43.20M57.06M83.31M89.07M90.17M75.06M143.46M
Gross Profit22.08M44.29M46.05M44.73M42.54M41.47M56.43M
Gross Margin33.82%43.70%35.60%33.43%32.06%35.59%28.23%
Operating Expense52.73M58.38M68.78M89.18M101.73M122.75M113.03M
Operating Income-30.65M-14.09M-22.73M-44.45M-59.19M-81.28M-56.60M
Operating Margin-46.95%-13.90%-17.58%-33.22%-44.60%-69.75%-28.31%
EBITDA-30.42M2.82M-6.83M-22.01M-41.85M-46.75M-32.81M
EBITDA Margin-46.60%2.79%-5.28%-16.45%-31.54%-40.12%-16.41%
Net Income-35.11M-11.21M-23.43M-42.72M-72.65M-82.86M-73.00M
Net Income Margin-53.78%-11.06%-18.12%-31.93%-54.74%-71.11%-36.52%
R&D12.09M8.72M15.48M29.69M30.34M29.63M40.64M
R&D as % of Total Revenue18.51%8.60%11.97%22.19%22.86%25.42%20.33%
Interest Expense157.00K356.00K307.00K203.00K7.91M12.10M14.46M
Interest Expense % of Total Revenue0.24%0.35%0.24%0.15%5.96%10.38%7.23%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets172.23M449.91M419.12M384.27M1.05B1.00B988.37M
Total Liabilities41.48M40.35M36.90M44.52M602.85M654.08M709.93M
Total Equity130.75M409.56M382.22M339.75M444.10M349.06M278.43M
Cash45.32M212.77M104.29M76.86M68.53M92.34M56.49M
Total Debt18.76M21.63M14.74M9.43M571.10M616.49M-
Net Debt-26.57M-191.14M-89.55M-67.43M502.56M524.14M595.45M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-23.71M-12.78M-19.30M-23.47M-77.54M-44.82M-66.99M
Investing Cash Flow23.30M-73.56M-82.28M4.90M-657.43M21.10M-
Financing Cash Flow-3.08M253.72M-6.89M-9.18M726.65M47.28M-
Capital Expenditure639.00K9.04M18.67M10.58M667.81M66.98M9.41M
Free Cash Flow-24.35M-21.82M-37.98M-34.05M-745.35M-111.80M-76.39M
FCF to OCF102.70%170.76%196.71%145.09%961.29%249.43%114.04%

Key Statistics & Ratios

Market Cap375.96M
Enterprise Value1.23B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.00
Price / Book1.84
EPS-1.04
Book Value5.16
Revenue (TTM)187.88M
Gross Profit (TTM)52.63M
EBITDA-25.47M
Profit Margin-27.82%
Operating Margin-27.57%
Return on Equity-18.32%
Return on Assets-2.97%
Shares Outstanding50.47M
Shares Float29.85M
Beta0.01
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%